venBio Global Strategic Fund II L.P. - 27 Apr 2022 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc.

Role
10%+ Owner
Signature
venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
27 Apr 2022
Net transactions value
-$1,972,579
Form type
4
Filing time
29 Apr 2022, 17:50:56 UTC
Previous filing
26 Apr 2022
Next filing
04 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMPI Common Stock Sale $491,980 -47,396 -1.6% $10.38 2,948,463 27 Apr 2022 Direct F1, F4
transaction CMPI Common Stock Sale $761,936 -73,400 -2.5% $10.38 2,875,063 28 Apr 2022 Direct F2, F4
transaction CMPI Common Stock Sale $718,663 -69,230 -2.4% $10.38 2,805,833 29 Apr 2022 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.